Amarin Corporation plc (AMRN)
USD 0.4
(0.32%)
USD 0.4
(0.32%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -50.9 Million USD | 83.96% |
| 2022 | -100.64 Million USD | -459.09% |
| 2021 | 14.27 Million USD | 271.58% |
| 2020 | -12.71 Million USD | 7.6% |
| 2019 | -15.05 Million USD | 85.39% |
| 2018 | -106.62 Million USD | -144.79% |
| 2017 | -44.81 Million USD | 32.92% |
| 2016 | -56.52 Million USD | 32.85% |
| 2015 | -97.41 Million USD | -6.75% |
| 2014 | -39.77 Million USD | 48.62% |
| 2013 | -134.61 Million USD | -54.5% |
| 2012 | -152.31 Million USD | -164.93% |
| 2011 | -66.79 Million USD | -127.42% |
| 2010 | -249.9 Million USD | 640.88% |
| 2009 | -55.16 Million USD | -61.55% |
| 2008 | -19.87 Million USD | 43.14% |
| 2007 | -38.43 Million USD | -2.5% |
| 2006 | -31.16 Million USD | -87.0% |
| 2005 | -19.28 Million USD | 50.11% |
| 2004 | -9.85 Million USD | 37.61% |
| 2003 | -6.09 Million USD | -1382.11% |
| 2002 | -25.44 Million USD | -73.88% |
| 2001 | 16.14 Million USD | 3315.57% |
| 2000 | -224 Thousand USD | 83.53% |
| 1999 | -4.81 Million USD | -78.88% |
| 1998 | -7.9 Million USD | 55.26% |
| 1997 | -5.6 Million USD | 79.79% |
| 1996 | -17.1 Million USD | -500.0% |
| 1995 | 5.6 Million USD | -74.87% |
| 1994 | 18.7 Million USD | 1235.71% |
| 1993 | 1.7 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | -25.16 Million USD | -10401.69% |
| 2024 Q2 | 237.26 Thousand USD | 101.85% |
| 2024 Q1 | -12.81 Million USD | -644.61% |
| 2023 Q4 | -3.9 Million USD | 79.75% |
| 2023 Q2 | -3.16 Million USD | 80.92% |
| 2023 FY | - USD | 83.96% |
| 2023 Q3 | -19.29 Million USD | -510.02% |
| 2023 Q1 | -16.57 Million USD | -138.43% |
| 2022 Q1 | -27.52 Million USD | -271.85% |
| 2022 Q2 | -41.62 Million USD | -51.22% |
| 2022 Q4 | -6.95 Million USD | -365.75% |
| 2022 FY | - USD | -459.09% |
| 2022 Q3 | 2.61 Million USD | 106.28% |
| 2021 FY | - USD | 271.58% |
| 2021 Q3 | 2.32 Million USD | -76.03% |
| 2021 Q1 | -437 Thousand USD | -105.63% |
| 2021 Q2 | 9.68 Million USD | 2315.56% |
| 2021 Q4 | 16.01 Million USD | 590.13% |
| 2020 Q4 | 7.76 Million USD | 244.13% |
| 2020 FY | - USD | 7.6% |
| 2020 Q3 | -5.38 Million USD | -194.24% |
| 2020 Q2 | 5.71 Million USD | 126.94% |
| 2020 Q1 | -21.21 Million USD | -344.67% |
| 2019 FY | - USD | 85.39% |
| 2019 Q4 | 8.67 Million USD | 628.4% |
| 2019 Q3 | -1.64 Million USD | -2053.57% |
| 2019 Q2 | 84 Thousand USD | 100.37% |
| 2019 Q1 | -22.43 Million USD | 29.82% |
| 2018 Q4 | -31.96 Million USD | -44.97% |
| 2018 FY | - USD | -144.79% |
| 2018 Q1 | -21.59 Million USD | -217.51% |
| 2018 Q2 | -31.76 Million USD | -47.1% |
| 2018 Q3 | -22.04 Million USD | 30.58% |
| 2017 Q3 | -8.2 Million USD | 25.43% |
| 2017 Q2 | -10.99 Million USD | 40.06% |
| 2017 FY | - USD | 32.92% |
| 2017 Q1 | -18.34 Million USD | -41.54% |
| 2017 Q4 | -6.8 Million USD | 17.08% |
| 2016 Q4 | -12.96 Million USD | 14.34% |
| 2016 Q3 | -15.13 Million USD | -5.83% |
| 2016 Q2 | -14.29 Million USD | 37.84% |
| 2016 Q1 | -23 Million USD | -22.91% |
| 2016 FY | - USD | 32.85% |
| 2015 Q2 | -26.38 Million USD | 2.13% |
| 2015 Q4 | -18.71 Million USD | 27.18% |
| 2015 Q3 | -25.7 Million USD | 2.6% |
| 2015 Q1 | -26.96 Million USD | -31.73% |
| 2015 FY | - USD | -6.75% |
| 2014 FY | - USD | 48.62% |
| 2014 Q1 | -25.32 Million USD | 16.51% |
| 2014 Q3 | -24.97 Million USD | -20.28% |
| 2014 Q2 | -20.76 Million USD | 18.04% |
| 2014 Q4 | -20.46 Million USD | 18.03% |
| 2013 Q1 | -59.95 Million USD | 42.75% |
| 2013 FY | - USD | -54.5% |
| 2013 Q3 | -40.43 Million USD | 17.46% |
| 2013 Q4 | -30.33 Million USD | 24.97% |
| 2013 Q2 | -48.98 Million USD | 18.3% |
| 2012 Q1 | 47.39 Million USD | 172.42% |
| 2012 FY | - USD | -164.93% |
| 2012 Q4 | -104.71 Million USD | -108.03% |
| 2012 Q3 | -50.33 Million USD | -480.19% |
| 2012 Q2 | -8.67 Million USD | -118.31% |
| 2011 Q3 | -115.98 Million USD | -168.2% |
| 2011 Q4 | -65.43 Million USD | 43.58% |
| 2011 Q1 | -7.15 Million USD | 86.0% |
| 2011 FY | - USD | -127.42% |
| 2011 Q2 | 170.05 Million USD | 2475.43% |
| 2010 Q2 | 20.17 Million USD | 373.11% |
| 2010 Q4 | -51.14 Million USD | -508.57% |
| 2010 Q1 | -7.38 Million USD | 0.0% |
| 2010 FY | - USD | 640.88% |
| 2010 Q3 | -8.4 Million USD | -141.65% |
| 2009 FY | - USD | -61.55% |
| 2009 Q4 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2008 Q1 | -7.82 Million USD | 3.86% |
| 2008 FY | - USD | 43.14% |
| 2008 Q2 | 6.74 Million USD | 186.21% |
| 2007 Q3 | -6.89 Million USD | 57.65% |
| 2007 Q4 | -8.14 Million USD | -18.19% |
| 2007 FY | - USD | -2.5% |
| 2007 Q2 | -16.26 Million USD | -71.17% |
| 2007 Q1 | -9.5 Million USD | 6.03% |
| 2006 Q3 | -8.08 Million USD | -4.0% |
| 2006 Q1 | -5.54 Million USD | 70.03% |
| 2006 Q4 | -10.11 Million USD | -25.05% |
| 2006 FY | - USD | -87.0% |
| 2006 Q2 | -7.77 Million USD | -40.23% |
| 2005 Q1 | -3.39 Million USD | 61.83% |
| 2005 FY | - USD | 50.11% |
| 2005 Q3 | 250 Thousand USD | 104.54% |
| 2005 Q4 | -18.5 Million USD | -7502.4% |
| 2005 Q2 | -5.5 Million USD | -61.89% |
| 2004 Q3 | -1.11 Million USD | 92.24% |
| 2004 Q4 | -8.9 Million USD | -697.05% |
| 2004 Q1 | 1.04 Million USD | 101.32% |
| 2004 Q2 | -14.39 Million USD | -1475.81% |
| 2004 FY | - USD | 37.61% |
| 2003 Q3 | 3.41 Million USD | 172.37% |
| 2003 Q1 | 14.87 Million USD | 117.44% |
| 2003 Q2 | -5.43 Million USD | -136.54% |
| 2003 FY | - USD | -1382.11% |
| 2003 Q4 | 1.5 Million USD | -2112.28% |
| 2002 Q4 | -85.3 Million USD | -675.5% |
| 2002 Q3 | 14.82 Million USD | 52.96% |
| 2002 Q2 | 9.69 Million USD | -44.96% |
| 2002 Q1 | 17.6 Million USD | 140.4% |
| 2002 FY | - USD | -73.88% |
| 2001 Q3 | 15.88 Million USD | -5.46% |
| 2001 Q4 | -43.57 Million USD | -374.39% |
| 2001 FY | - USD | 3315.57% |
| 2001 Q1 | 5.81 Million USD | 137.24% |
| 2001 Q2 | 16.8 Million USD | 188.76% |
| 2000 Q1 | 4.32 Million USD | 0.0% |
| 2000 Q3 | 5.35 Million USD | 50.0% |
| 2000 Q2 | 3.56 Million USD | -17.48% |
| 2000 Q4 | -15.62 Million USD | -391.87% |
| 2000 FY | - USD | 83.53% |
| 1999 Q1 | 5.1 Million USD | 13.33% |
| 1999 Q3 | 3.3 Million USD | -44.07% |
| 1999 FY | - USD | -78.88% |
| 1999 Q2 | 5.9 Million USD | 15.69% |
| 1998 Q3 | -30.6 Million USD | -765.22% |
| 1998 FY | - USD | 55.26% |
| 1998 Q4 | 4.5 Million USD | 114.71% |
| 1998 Q2 | 4.6 Million USD | 0.0% |
| 1998 Q1 | 4.6 Million USD | -4.17% |
| 1997 Q2 | 6.1 Million USD | 17.31% |
| 1997 FY | - USD | 79.79% |
| 1997 Q1 | 5.2 Million USD | -1.89% |
| 1997 Q4 | 4.8 Million USD | 119.51% |
| 1997 Q3 | -24.6 Million USD | -503.28% |
| 1996 Q3 | -30.7 Million USD | -830.95% |
| 1996 FY | - USD | -500.0% |
| 1996 Q1 | 4.1 Million USD | 0.0% |
| 1996 Q4 | 5.3 Million USD | 117.26% |
| 1996 Q2 | 4.2 Million USD | 2.44% |
| 1995 Q2 | 7.3 Million USD | 0.0% |
| 1995 Q3 | -17.3 Million USD | -336.99% |
| 1995 Q1 | 7.3 Million USD | 0.0% |
| 1995 FY | - USD | -74.87% |
| 1995 Q4 | 4.1 Million USD | 123.7% |
| 1994 Q3 | 13.1 Million USD | 523.81% |
| 1994 Q4 | 7.3 Million USD | -44.27% |
| 1994 FY | - USD | 1235.71% |
| 1994 Q1 | 3.1 Million USD | 47.62% |
| 1994 Q2 | 2.1 Million USD | -32.26% |
| 1993 Q2 | 600 Thousand USD | 0.0% |
| 1993 FY | - USD | 0.0% |
| 1993 Q4 | 2.1 Million USD | 310.0% |
| 1993 Q3 | -1 Million USD | -266.67% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AbCellera Biologics Inc. | -192.15 Million USD | 73.511% |
| Alkermes plc | 495.04 Million USD | 110.282% |
| Agenus Inc. | -145.92 Million USD | 65.118% |
| Aptorum Group Limited | -9.59 Million USD | -430.28% |
| Ardelyx, Inc. | -55.35 Million USD | 8.044% |
| Dyadic International, Inc. | -8.22 Million USD | -518.507% |
| Eton Pharmaceuticals, Inc. | -291 Thousand USD | -17391.935% |
| Lantern Pharma Inc. | -15.78 Million USD | -222.433% |
| Inhibikase Therapeutics, Inc. | -19.91 Million USD | -155.627% |
| Novavax, Inc. | -487.39 Million USD | 89.556% |
| Janux Therapeutics, Inc. | -71.02 Million USD | 28.332% |
| Pyxis Oncology, Inc. | -78.49 Million USD | 35.152% |
| TransCode Therapeutics, Inc. | -17.97 Million USD | -183.204% |
| Ocuphire Pharma, Inc. | -9.96 Million USD | -410.649% |
| Outlook Therapeutics, Inc. | -57.37 Million USD | 11.284% |
| Madrigal Pharmaceuticals, Inc. | -379.96 Million USD | 86.604% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | -111.105% |
| SELLAS Life Sciences Group, Inc. | 529 Thousand USD | 9722.218% |
| Syros Pharmaceuticals, Inc. | -157.19 Million USD | 67.619% |
| Barinthus Biotherapeutics plc | -74.81 Million USD | 31.963% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | -152.5% |
| Xeris Biopharma Holdings, Inc. | -23.73 Million USD | -114.458% |
| Clearside Biomedical, Inc. | -23.05 Million USD | -120.754% |
| C4 Therapeutics, Inc. | -122.1 Million USD | 58.313% |
| Alnylam Pharmaceuticals, Inc. | -258.24 Million USD | 80.289% |
| AlloVir, Inc. | -190.14 Million USD | 73.23% |
| Arrowhead Pharmaceuticals, Inc. | -175.67 Million USD | 71.025% |
| VYNE Therapeutics Inc. | -29.25 Million USD | -73.975% |
| Bicycle Therapeutics plc | -183.4 Million USD | 72.246% |
| BioXcel Therapeutics, Inc. | -165.42 Million USD | 69.229% |
| ChromaDex Corporation | -3.89 Million USD | -1207.179% |
| Chimerix, Inc. | -92.97 Million USD | 45.252% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | -14.548% |
| Caribou Biosciences, Inc. | -112.53 Million USD | 54.768% |
| CRISPR Therapeutics AG | -202.7 Million USD | 74.888% |
| Precision BioSciences, Inc. | -32.04 Million USD | -58.859% |
| Fate Therapeutics, Inc. | -172.22 Million USD | 70.445% |
| Fortress Biotech, Inc. | -133.64 Million USD | 61.912% |
| Fortress Biotech, Inc. | -133.64 Million USD | 61.912% |
| HOOKIPA Pharma Inc. | -77.34 Million USD | 34.187% |
| ImmuCell Corporation | -2.5 Million USD | -1932.746% |
| IDEAYA Biosciences, Inc. | -130.42 Million USD | 60.971% |
| Immix Biopharma, Inc. | -16.13 Million USD | -215.46% |
| Incyte Corporation | 919.42 Million USD | 105.536% |
| Innoviva, Inc. | 248.96 Million USD | 120.446% |
| IO Biotech, Inc. | -91.22 Million USD | 44.204% |
| Jaguar Health, Inc. | -33.13 Million USD | -53.637% |
| Keros Therapeutics, Inc. | -152.17 Million USD | 66.551% |
| Ligand Pharmaceuticals Incorporated | 101.72 Million USD | 150.037% |
| ContextLogic Inc. | -324 Million USD | 84.29% |
| MiMedx Group, Inc. | 40.51 Million USD | 225.63% |
| MEI Pharma, Inc. | 26.38 Million USD | 292.955% |
| NextCure, Inc. | -59.03 Million USD | 13.783% |
| Onconetix, Inc. | -36.7 Million USD | -38.671% |
| Oncternal Therapeutics, Inc. | 2.23 Million USD | 2377.473% |
| Opthea Limited | -200.01 Million USD | 74.552% |
| Psyence Biomedical Ltd. | -2.75 Million USD | -1749.902% |
| Vaxcyte, Inc. | -464.88 Million USD | 89.051% |
| PDS Biotechnology Corporation | -40.08 Million USD | -26.984% |
| Precigen, Inc. | -89.22 Million USD | 42.952% |
| Pharming Group N.V. | 9.87 Million USD | 615.354% |
| Phathom Pharmaceuticals, Inc. | -159.04 Million USD | 67.996% |
| Pieris Pharmaceuticals, Inc. | -22.76 Million USD | -123.625% |
| PureTech Health plc | -11.62 Million USD | -337.787% |
| Rigel Pharmaceuticals, Inc. | -16.98 Million USD | -199.756% |
| Avidity Biosciences, Inc. | -233.49 Million USD | 78.2% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | -111.105% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | 41.778% |
| Sol-Gel Technologies Ltd. | -28.96 Million USD | -75.747% |
| Acelyrin, Inc. | -381.52 Million USD | 86.658% |
| Salarius Pharmaceuticals, Inc. | -12.88 Thousand USD | -394948.239% |
| Summit Therapeutics Inc. | 1 Million USD | 5185.068% |
| Sensei Biotherapeutics, Inc. | -33.38 Million USD | -52.464% |
| Senti Biosciences, Inc. | -61.33 Million USD | 17.012% |
| Stoke Therapeutics, Inc. | -112.3 Million USD | 54.675% |
| Elevation Oncology, Inc. | -41.46 Million USD | -22.752% |
| Alaunos Therapeutics, Inc. | -30.9 Million USD | -64.709% |
| Telomir Pharmaceuticals, Inc. Common Stock | -6.11 Million USD | -732.194% |
| Entrada Therapeutics, Inc. | -321 Thousand USD | -15757.175% |
| VistaGen Therapeutics, Inc. | -32.45 Million USD | -56.847% |
| Kintara Therapeutics, Inc. | -8.39 Million USD | -506.259% |
| Wave Life Sciences Ltd. | -58.79 Million USD | 13.418% |
| Seer, Inc. | -97.88 Million USD | 47.999% |
| Verrica Pharmaceuticals Inc. | -62.19 Million USD | 18.161% |
| Aadi Bioscience, Inc. | -65.36 Million USD | 22.127% |
| ESSA Pharma Inc. | -26.45 Million USD | -92.406% |
| GlycoMimetics, Inc. | -39.12 Million USD | -30.11% |
| GT Biopharma, Inc. | 5.97 Million USD | 951.339% |
| Inhibrx Biosciences, Inc. | -206.69 Million USD | 75.373% |
| Akebia Therapeutics, Inc. | -6.86 Million USD | -641.141% |
| Catalyst Pharmaceuticals, Inc. | 86.81 Million USD | 158.634% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | 10.312% |
| Orchestra BioMed Holdings, Inc. | -51.21 Million USD | 0.62% |
| Alzamend Neuro, Inc. | -9.88 Million USD | -414.838% |
| Sorrento Therapeutics, Inc. | -539.92 Million USD | 90.573% |
| TRACON Pharmaceuticals, Inc. | -6.88 Million USD | -639.418% |
| Viracta Therapeutics, Inc. | -46.86 Million USD | -8.62% |
| Rocket Pharmaceuticals, Inc. | -236.62 Million USD | 78.488% |
| Aptose Biosciences Inc. | -52.26 Million USD | 2.614% |
| ZyVersa Therapeutics, Inc. | -107.74 Million USD | 52.757% |
| Soligenix, Inc. | -7.85 Million USD | -548.192% |
| Century Therapeutics, Inc. | -121.2 Million USD | 58.005% |
| Kura Oncology, Inc. | -164.95 Million USD | 69.142% |
| TScan Therapeutics, Inc. | -80.09 Million USD | 36.451% |
| Intensity Therapeutics, Inc. | -10.08 Million USD | -404.675% |
| Ocean Biomedical, Inc. | -957.73 Thousand USD | -5214.76% |
| CytomX Therapeutics, Inc. | -4.3 Million USD | -1081.284% |
| Autolus Therapeutics plc | -156.77 Million USD | 67.531% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | 39.873% |
| EyePoint Pharmaceuticals, Inc. | -69 Million USD | 26.231% |
| Eterna Therapeutics Inc. | -19.93 Million USD | -155.35% |
| Adaptive Biotechnologies Corporation | -189.27 Million USD | 73.107% |
| GRI Bio, Inc. | -10.89 Million USD | -367.072% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | -1027.209% |
| Tenaya Therapeutics, Inc. | -122.5 Million USD | 58.45% |
| IGM Biosciences, Inc. | -253.35 Million USD | 79.909% |
| INmune Bio, Inc. | - USD | Infinity% |
| Heron Therapeutics, Inc. | -103.79 Million USD | 50.958% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | -33.483% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | -232.019% |
| Entero Therapeutics, Inc. | -15.74 Million USD | -223.323% |
| Milestone Pharmaceuticals Inc. | -56.84 Million USD | 10.456% |
| X4 Pharmaceuticals, Inc. | -107.1 Million USD | 52.474% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 80.864% |
| Coherus BioSciences, Inc. | -193.93 Million USD | 73.754% |
| Verastem, Inc. | -83.16 Million USD | 38.795% |
| Abeona Therapeutics Inc. | -50.57 Million USD | -0.652% |
| Pliant Therapeutics, Inc. | -158.22 Million USD | 67.83% |
| Tonix Pharmaceuticals Holding Corp. | -114.08 Million USD | 55.384% |
| Histogen Inc. | -10.5 Million USD | -384.638% |
| Aprea Therapeutics, Inc. | -14.27 Million USD | -256.461% |
| Surrozen, Inc. | -41.13 Million USD | -23.755% |
| Organovo Holdings, Inc. | -14.8 Million USD | -243.79% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | 1587300.842% |
| Ovid Therapeutics Inc. | -58.71 Million USD | 13.305% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 0.765% |
| CASI Pharmaceuticals, Inc. | -21.53 Million USD | -136.323% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.33 Million USD | -510.476% |
| Centessa Pharmaceuticals plc | -166.06 Million USD | 69.349% |
| Hepion Pharmaceuticals, Inc. | -49.25 Million USD | -3.336% |
| Arcturus Therapeutics Holdings Inc. | -24.16 Million USD | -110.633% |
| BioRestorative Therapies, Inc. | -15.05 Million USD | -238.103% |
| Apollomics, Inc. | -171.74 Million USD | 70.362% |
| Mesoblast Limited | -61.33 Million USD | 17.005% |
| Turnstone Biologics Corp. | -56.23 Million USD | 9.483% |
| Kymera Therapeutics, Inc. | -143.2 Million USD | 64.454% |
| Synaptogenix, Inc. | -8.3 Million USD | -512.717% |
| Tiziana Life Sciences Ltd | -15.33 Million USD | -231.844% |
| Aurinia Pharmaceuticals Inc. | -63.04 Million USD | 19.264% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | -962.337% |
| Monopar Therapeutics Inc. | 429.03 Thousand USD | 11964.08% |
| Exelixis, Inc. | 196.6 Million USD | 125.891% |
| Better Therapeutics, Inc. | -38.26 Million USD | -33.034% |
| Nurix Therapeutics, Inc. | -141.4 Million USD | 64.004% |
| Apellis Pharmaceuticals, Inc. | -495.21 Million USD | 89.721% |
| NLS Pharmaceutics AG | -11.79 Million USD | -331.528% |
| Dermata Therapeutics, Inc. | 247.21 Thousand USD | 20689.902% |
| Aridis Pharmaceuticals, Inc. | -29.5 Million USD | -72.512% |
| Gritstone bio, Inc. | -126.86 Million USD | 59.877% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | 21.672% |
| TNF Pharmaceuticals, Inc. | -3.99 Million USD | -1172.555% |
| Avid Bioservices, Inc. | -11.48 Million USD | -343.355% |
| Insmed Incorporated | -654.73 Million USD | 92.226% |
| Virpax Pharmaceuticals, Inc. | -2.24 Million USD | -2162.573% |
| MediWound Ltd. | -4.89 Million USD | -940.293% |
| OmniAb, Inc. | -49.73 Million USD | -2.354% |
| Alector, Inc. | -142.89 Million USD | 64.378% |
| Seres Therapeutics, Inc. | -85.43 Million USD | 40.42% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | 2.39% |
| Zai Lab Limited | -366.57 Million USD | 86.114% |
| Revance Therapeutics, Inc. | -290.63 Million USD | 82.486% |
| Aura Biosciences, Inc. | -83.69 Million USD | 39.183% |
| Lyell Immunopharma, Inc. | -225.24 Million USD | 77.402% |
| Immunic, Inc. | -99.11 Million USD | 48.642% |
| Tarsus Pharmaceuticals, Inc. | -131.67 Million USD | 61.342% |
| Veracyte, Inc. | -49.4 Million USD | -3.021% |
| InMed Pharmaceuticals Inc. | -7.06 Million USD | -620.584% |
| FibroGen, Inc. | -261.4 Million USD | 80.528% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | -356.885% |
| Adial Pharmaceuticals, Inc. | -7 Million USD | -627.027% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.71 Million USD | -171.955% |
| Jazz Pharmaceuticals plc | 1.44 Billion USD | 103.512% |
| Cyclacel Pharmaceuticals, Inc. | -25.42 Million USD | -100.226% |
| Amylyx Pharmaceuticals, Inc. | 39.89 Million USD | 227.605% |
| TG Therapeutics, Inc. | 26.1 Million USD | 295.025% |
| Galecto, Inc. | -37.51 Million USD | -35.669% |
| Calithera Biosciences, Inc. | -38.26 Million USD | -33.024% |
| Fortrea Holdings Inc. | 167.3 Million USD | 130.425% |
| KalVista Pharmaceuticals, Inc. | -134.28 Million USD | 62.093% |
| Aptevo Therapeutics Inc. | -28.31 Million USD | -79.794% |
| XBiotech Inc. | -35.76 Million USD | -42.318% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | 21.672% |
| Lyra Therapeutics, Inc. | -65.25 Million USD | 21.99% |
| Foghorn Therapeutics Inc. | -104.45 Million USD | 51.269% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | -98.276% |
| Theravance Biopharma, Inc. | -40.86 Million USD | -24.554% |
| Ultragenyx Pharmaceutical Inc. | -516.45 Million USD | 90.144% |
| Metagenomi, Inc. Common Stock | -56.02 Million USD | 9.138% |
| Vaxxinity, Inc. | -56.05 Thousand USD | -90712.886% |
| BioCryst Pharmaceuticals, Inc. | -116.33 Million USD | 56.246% |
| Gain Therapeutics, Inc. | -22.16 Million USD | -129.601% |
| Cartesian Therapeutics, Inc. | -235.06 Million USD | 78.346% |
| NexImmune, Inc. | -28.16 Million USD | -80.71% |
| Creative Medical Technology Holdings, Inc. | -5.52 Million USD | -821.203% |
| Marker Therapeutics, Inc. | -11.79 Million USD | -331.652% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 101.094% |
| Chemomab Therapeutics Ltd. | -25.39 Million USD | -100.463% |
| Scopus BioPharma Inc. | -11.71 Million USD | -334.567% |
| RAPT Therapeutics, Inc. | -125.84 Million USD | 59.553% |
| Ainos, Inc. | -8.77 Million USD | -480.2% |
| Pluri Inc. | -20.22 Million USD | -151.676% |
| Prothena Corporation plc | -190.1 Million USD | 73.225% |
| Adaptimmune Therapeutics plc | -128.19 Million USD | 60.295% |
| Celularity Inc. | -183.94 Million USD | 72.328% |
| Rallybio Corporation | -72.37 Million USD | 29.668% |
| Cue Biopharma, Inc. | -46.05 Million USD | -10.531% |
| MeiraGTx Holdings plc | -57.05 Million USD | 10.78% |
| Omeros Corporation | -163.61 Million USD | 68.888% |
| Humacyte, Inc. | -96.45 Million USD | 47.229% |
| Immunocore Holdings plc | -59.64 Million USD | 14.665% |
| Cocrystal Pharma, Inc. | -19.37 Million USD | -162.758% |
| Cidara Therapeutics, Inc. | -24.36 Million USD | -108.913% |
| Blueprint Medicines Corporation | -474.61 Million USD | 89.275% |
| CalciMedica, Inc. | -34.18 Million USD | -48.883% |
| Cabaletta Bio, Inc. | -73.23 Million USD | 30.495% |
| Marinus Pharmaceuticals, Inc. | -125.49 Million USD | 59.44% |
| Scholar Rock Holding Corporation | -168.45 Million USD | 69.783% |
| Sana Biotechnology, Inc. | -252.39 Million USD | 79.832% |
| Pulmatrix, Inc. | -12.64 Million USD | -302.511% |
| Elicio Therapeutics, Inc. | -32.96 Million USD | -54.406% |
| Vigil Neuroscience, Inc. | -88.46 Million USD | 42.463% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 89.947% |
| Adlai Nortye Ltd. American Depositary Shares | -101.21 Million USD | 49.709% |
| Cytokinetics, Incorporated | -456.68 Million USD | 88.854% |
| Eloxx Pharmaceuticals, Inc. | -33.37 Million USD | -52.523% |
| Nutriband Inc. | -5.12 Million USD | -893.826% |
| Protara Therapeutics, Inc. | -43.27 Million USD | -17.632% |
| Vor Biopharma Inc. | -114.37 Million USD | 55.494% |
| Roivant Sciences Ltd. | -996.51 Million USD | 94.892% |
| Evogene Ltd. | -23.2 Million USD | -119.365% |
| ProKidney Corp. | -147.66 Million USD | 65.53% |
| Applied Therapeutics, Inc. | -64.53 Million USD | 21.126% |
| Hoth Therapeutics, Inc. | -153.14 Thousand USD | -33136.607% |
| BridgeBio Pharma, Inc. | -565.46 Million USD | 90.998% |
| CorMedix Inc. | -48.88 Million USD | -4.121% |
| BioLineRx Ltd. | -57.06 Million USD | 10.795% |
| Tango Therapeutics, Inc. | -111.75 Million USD | 54.454% |
| Galectin Therapeutics Inc. | -202 Thousand USD | -25098.778% |
| Atai Life Sciences N.V. | -36.31 Million USD | -40.182% |
| Renovaro Biosciences Inc. | -79.51 Million USD | 35.987% |
| Aerovate Therapeutics, Inc. | -81.31 Million USD | 37.401% |
| Zentalis Pharmaceuticals, Inc. | -275.5 Million USD | 81.524% |
| Sagimet Biosciences Inc. | -30.74 Million USD | -65.587% |
| MediciNova, Inc. | -9.87 Million USD | -415.199% |
| Praxis Precision Medicines, Inc. | -125.94 Million USD | 59.583% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | -3226.46% |
| GeoVax Labs, Inc. | -26.66 Million USD | -90.866% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 77.376% |
| Biomea Fusion, Inc. | -124.62 Million USD | 59.155% |
| PTC Therapeutics, Inc. | -330.34 Million USD | 84.591% |
| Mereo BioPharma Group plc | -26.05 Million USD | -95.354% |
| Cullinan Oncology, Inc. | -190.33 Million USD | 73.257% |
| Syndax Pharmaceuticals, Inc. | -229.94 Million USD | 77.863% |
| Absci Corporation | -95.45 Million USD | 46.676% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | -69.53% |
| 4D Molecular Therapeutics, Inc. | -107.11 Million USD | 52.481% |
| Dyne Therapeutics, Inc. | -233.47 Million USD | 78.198% |
| Kiniksa Pharmaceuticals, Ltd. | -22.85 Million USD | -122.715% |
| Ventyx Biosciences, Inc. | -207.83 Million USD | 75.509% |
| Allakos Inc. | -189.91 Million USD | 73.198% |
| Imunon, Inc. | -19.87 Million USD | -156.066% |
| Fulcrum Therapeutics, Inc. | -108.49 Million USD | 53.083% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 146.99% |
| BioAtla, Inc. | -122.24 Million USD | 58.36% |
| NLS Pharmaceutics AG | -11.79 Million USD | -331.528% |
| Bio-Path Holdings, Inc. | -15.76 Million USD | -222.959% |
| Allogene Therapeutics, Inc. | -300.29 Million USD | 83.049% |
| Larimar Therapeutics, Inc. | -41.44 Million USD | -22.811% |
| XOMA Corporation | -39.36 Million USD | -29.316% |
| Kezar Life Sciences, Inc. | -99.25 Million USD | 48.716% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 56.735% |
| aTyr Pharma, Inc. | -52.17 Million USD | 2.446% |
| Aligos Therapeutics, Inc. | -83.81 Million USD | 39.269% |
| Akero Therapeutics, Inc. | -148.63 Million USD | 65.753% |
| Viridian Therapeutics, Inc. | -234.56 Million USD | 78.3% |
| Eliem Therapeutics, Inc. | -13.65 Million USD | -272.823% |
| EyeGate Pharmaceuticals, Inc. | -8.04 Million USD | -532.923% |
| Akari Therapeutics, Plc | -16.8 Million USD | -202.949% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | 27073.987% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 111.263% |
| Lexaria Bioscience Corp. | -6.38 Million USD | -696.753% |
| UroGen Pharma Ltd. | -63.83 Million USD | 20.256% |
| Sutro Biopharma, Inc. | -67.91 Million USD | 25.051% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | -600.832% |
| Orgenesis Inc. | -60.71 Million USD | 16.167% |
| Entera Bio Ltd. | -8.8 Million USD | -478.164% |
| GH Research PLC | -41.15 Million USD | -23.689% |
| Lisata Therapeutics, Inc. | -25.51 Million USD | -99.465% |
| Reneo Pharmaceuticals, Inc. | -82.23 Million USD | 38.101% |
| Xencor, Inc. | -125.87 Million USD | 59.562% |
| 60 Degrees Pharmaceuticals, Inc. | -1.42 Million USD | -3468.169% |
| Replimune Group, Inc. | -230.19 Million USD | 77.888% |
| Coeptis Therapeutics Holdings, Inc. | -20.15 Million USD | -152.518% |
| Vanda Pharmaceuticals Inc. | -10.94 Million USD | -365.194% |
| Lexaria Bioscience Corp. | -6.38 Million USD | -696.753% |
| Portage Biotech Inc. | -18.19 Million USD | -179.694% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | -3226.46% |
| Olema Pharmaceuticals, Inc. | -104.58 Million USD | 51.33% |
| OncoCyte Corporation | -23.12 Million USD | -120.134% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | -350.442% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | -344.289% |
| Purple Biotech Ltd. | -22.22 Million USD | -129.028% |
| CollPlant Biotechnologies Ltd. | -6.41 Million USD | -694.096% |
| scPharmaceuticals Inc. | -46.06 Million USD | -10.509% |
| ProMIS Neurosciences, Inc. | -17.8 Million USD | -185.808% |
| HilleVax, Inc. | -132.46 Million USD | 61.574% |
| NeuroSense Therapeutics Ltd. | -10.63 Million USD | -378.713% |
| Tharimmune, Inc. | -9.3 Million USD | -447.176% |
| Genprex, Inc. | -31.06 Million USD | -63.878% |
| Neumora Therapeutics, Inc. Common Stock | -187.52 Million USD | 72.856% |
| Atossa Therapeutics, Inc. | -31.35 Million USD | -62.345% |
| XTL Biopharmaceuticals Ltd. | -764 Thousand USD | -6562.504% |
| Virios Therapeutics, Inc. | 150.9 Thousand USD | 33831.068% |
| OKYO Pharma Limited | -15.74 Thousand USD | -323169.092% |
| Savara Inc. | -59.13 Million USD | 13.92% |
| Curis, Inc. | -45.13 Million USD | -12.766% |
| Daré Bioscience, Inc. | -30.7 Million USD | -65.795% |
| Carmell Therapeutics Corporation | -15.19 Million USD | -235.074% |
| Titan Pharmaceuticals, Inc. | -7.16 Million USD | -610.419% |
| Achieve Life Sciences, Inc. | -26.73 Million USD | -90.4% |
| BeiGene, Ltd. | -1.12 Billion USD | 95.474% |
| Kiromic BioPharma, Inc. | -16.3 Million USD | -212.256% |
| Revolution Medicines, Inc. Warrant | -430.58 Million USD | 88.178% |
| Protagonist Therapeutics, Inc. | -90.34 Million USD | 43.656% |
| Erasca, Inc. | -121.31 Million USD | 58.04% |
| bluebird bio, Inc. | -167.16 Million USD | 69.549% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | -1031.458% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 116.405% |
| DBV Technologies S.A. | -85.98 Million USD | 40.8% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | -1031.458% |
| Moderna, Inc. | -3.28 Billion USD | 98.45% |
| Vincerx Pharma, Inc. | -42.6 Million USD | -19.462% |
| Fresh Tracks Therapeutics, Inc. | -5.64 Million USD | -801.231% |
| Molecular Templates, Inc. | 1.43 Million USD | 3659.548% |
| Acrivon Therapeutics, Inc. Common Stock | -59.85 Million USD | 14.954% |
| Travere Therapeutics, Inc. | -326.24 Million USD | 84.398% |
| Monte Rosa Therapeutics, Inc. | -137.08 Million USD | 62.87% |
| Spruce Biosciences, Inc. | -47.36 Million USD | -7.464% |
| Celldex Therapeutics, Inc. | -139.03 Million USD | 63.389% |
| Cogent Biosciences, Inc. | -205.86 Million USD | 75.274% |
| MacroGenics, Inc. | 2.01 Million USD | 2623.626% |
| RenovoRx, Inc. | -11.39 Million USD | -346.897% |
| Adicet Bio, Inc. | -136.53 Million USD | 62.719% |
| Prime Medicine, Inc. | -193.75 Million USD | 73.729% |
| Aditxt, Inc. | -25.45 Million USD | -99.943% |
| Adagene Inc. | -14.95 Million USD | -240.461% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -596.318% |
| Quantum-Si incorporated | -91.8 Million USD | 44.554% |
| Maravai LifeSciences Holdings, Inc. | 712.4 Million USD | 107.145% |
| Acurx Pharmaceuticals, Inc. | - USD | Infinity% |
| Voyager Therapeutics, Inc. | 126.45 Million USD | 140.253% |
| SciSparc Ltd. | -5.28 Million USD | -863.679% |
| Vericel Corporation | 2.86 Million USD | 1877.288% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | -53363.502% |
| Minerva Neurosciences, Inc. | -21.69 Million USD | -134.662% |
| Generation Bio Co. | -133.3 Million USD | 61.814% |
| Astria Therapeutics, Inc. | -83.03 Million USD | 38.695% |
| Black Diamond Therapeutics, Inc. | -86.02 Million USD | 40.828% |
| Arcutis Biotherapeutics, Inc. | -227.43 Million USD | 77.619% |
| Invivyd, Inc. | -196.61 Million USD | 74.111% |
| Relay Therapeutics, Inc. | -374.15 Million USD | 86.396% |
| Quoin Pharmaceuticals, Ltd. | -9.27 Million USD | -448.816% |
| Spero Therapeutics, Inc. | 27.15 Million USD | 287.455% |
| Artelo Biosciences, Inc. | -10.28 Million USD | -394.91% |
| 2seventy bio, Inc. | -206.41 Million USD | 75.341% |
| ADMA Biologics, Inc. | 5.12 Million USD | 1094.171% |
| Clene Inc. | -43.24 Million USD | -17.716% |
| Capricor Therapeutics, Inc. | -23 Million USD | -121.225% |
| Boundless Bio, Inc. Common Stock | -48.47 Million USD | -5.001% |
| GeoVax Labs, Inc. | -26.66 Million USD | -90.866% |
| Recursion Pharmaceuticals, Inc. | -299.56 Million USD | 83.008% |
| Citius Pharmaceuticals, Inc. | -36.72 Million USD | -38.585% |
| Contineum Therapeutics, Inc. Class A Common Stock | 23.57 Million USD | 315.931% |
| Relmada Therapeutics, Inc. | 4.91 Million USD | 1136.637% |
| Finch Therapeutics Group, Inc. | -32.48 Million USD | -56.707% |
| ALX Oncology Holdings Inc. | -158.4 Million USD | 67.866% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 92.562% |
| Evaxion Biotech A/S | -21.4 Million USD | -137.824% |
| Ocular Therapeutix, Inc. | -66.41 Million USD | 23.358% |
| Verve Therapeutics, Inc. | -217.66 Million USD | 76.615% |
| Trevena, Inc. | -35.28 Million USD | -44.246% |
| Surrozen, Inc. | -41.13 Million USD | -23.755% |
| Tyra Biosciences, Inc. | -79.59 Million USD | 36.047% |
| Cingulate Inc. | -22.95 Million USD | -121.774% |
| Galmed Pharmaceuticals Ltd. | -7.46 Million USD | -582.235% |
| Unity Biotechnology, Inc. | -37.28 Million USD | -36.527% |
| Tenax Therapeutics, Inc. | -8.22 Million USD | -518.76% |
| Terns Pharmaceuticals, Inc. | -102.26 Million USD | 50.226% |
| ACADIA Pharmaceuticals Inc. | -67.82 Million USD | 24.954% |
| Connect Biopharma Holdings Limited | -58.37 Million USD | 12.798% |
| Clearmind Medicine Inc. | -8.71 Million USD | -484.359% |
| Kronos Bio, Inc. | -121.83 Million USD | 58.219% |
| Bolt Biotherapeutics, Inc. | -74.34 Million USD | 31.531% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | -1984.92% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 49.516% |
| Statera Biopharma, Inc. | 38.93 Million USD | 230.735% |
| ImmunityBio, Inc. | -436.18 Million USD | 88.33% |
| Korro Bio, Inc. | -80.9 Million USD | 37.084% |
| Kineta, Inc. | -15.71 Million USD | -223.925% |
| BioVie Inc. | -31.95 Million USD | -59.315% |
| Codexis, Inc. | -49.28 Million USD | -3.284% |
| Celularity Inc. | -183.94 Million USD | 72.328% |
| Crinetics Pharmaceuticals, Inc. | -221.51 Million USD | 77.021% |
| Celcuity Inc. | -58.3 Million USD | 12.705% |
| Virax Biolabs Group Limited | -6.6 Million USD | -670.168% |
| Cibus, Inc. | -314.58 Million USD | 83.819% |
| Eledon Pharmaceuticals, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.73 Million USD | -50.895% |
| IN8bio, Inc. | -28.5 Million USD | -78.577% |
| Kodiak Sciences Inc. | -259.02 Million USD | 80.349% |
| Annexon, Inc. | -141.57 Million USD | 64.046% |
| Adverum Biotechnologies, Inc. | -112.59 Million USD | 54.794% |
| Assembly Biosciences, Inc. | -64.19 Million USD | 20.709% |
| Avalo Therapeutics, Inc. | -27.95 Million USD | -82.084% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 77.87% |
| Eyenovia, Inc. | -24.1 Million USD | -111.157% |
| Puma Biotechnology, Inc. | 44.78 Million USD | 213.66% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | -15610.349% |
| Xilio Therapeutics, Inc. | -73.8 Million USD | 31.031% |
| Arcellx, Inc. | -64.14 Million USD | 20.646% |
| Cardiff Oncology, Inc. | -45.01 Million USD | -13.079% |
| Enanta Pharmaceuticals, Inc. | -123.47 Million USD | 58.776% |
| Regulus Therapeutics Inc. | -30.88 Million USD | -64.826% |
| Moolec Science SA | -52.07 Million USD | 2.254% |
| Acumen Pharmaceuticals, Inc. | -51.6 Million USD | 1.365% |
| Geron Corporation | -174.78 Million USD | 70.877% |
| LAVA Therapeutics N.V. | -40.41 Million USD | -25.941% |
| Royalty Pharma plc | 1.88 Billion USD | 102.697% |
| Atea Pharmaceuticals, Inc. | -119.59 Million USD | 57.438% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | -445.905% |
| TFF Pharmaceuticals, Inc. | -20.74 Million USD | -145.418% |
| Mersana Therapeutics, Inc. | -166.08 Million USD | 69.351% |
| Humacyte, Inc. | -96.45 Million USD | 47.229% |
| Structure Therapeutics Inc. | -102.45 Million USD | 50.32% |
| 89bio, Inc. | -134.46 Million USD | 62.145% |
| PMV Pharmaceuticals, Inc. | -78.87 Million USD | 35.466% |
| Avenue Therapeutics, Inc. | 4.05 Million USD | 1356.208% |
| Genelux Corporation | -24.16 Million USD | -110.642% |
| Trevi Therapeutics, Inc. | -33.8 Million USD | -50.596% |
| Lexicon Pharmaceuticals, Inc. | -163.46 Million USD | 68.861% |
| Notable Labs, Ltd. | -14.4 Million USD | -253.483% |
| Liquidia Corporation | -70.05 Million USD | 27.336% |
| Mustang Bio, Inc. | -48.06 Million USD | -5.906% |
| Immunovant, Inc. | -269.97 Million USD | 81.146% |
| Quantum-Si incorporated | -91.8 Million USD | 44.554% |
| Arbutus Biopharma Corporation | -70.98 Million USD | 28.294% |
| DiaMedica Therapeutics Inc. | -19.3 Million USD | -163.629% |
| Vera Therapeutics, Inc. | -102.01 Million USD | 50.102% |
| Acasti Pharma Inc. | -11.3 Million USD | -350.416% |
| MiNK Therapeutics, Inc. | -22.25 Million USD | -128.738% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | -232.019% |
| Xenon Pharmaceuticals Inc. | -210.51 Million USD | 75.82% |
| Elevai Labs, Inc. Common Stock | -4.27 Million USD | -1091.978% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | -220.539% |
| Tempest Therapeutics, Inc. | -28.77 Million USD | -76.889% |
| Soleno Therapeutics, Inc. | -37.03 Million USD | -37.46% |
| PepGen Inc. | -83.58 Million USD | 39.1% |
| Moleculin Biotech, Inc. | -29.5 Million USD | -72.524% |
| United Therapeutics Corporation | 1.38 Billion USD | 103.67% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | -122.307% |
| Solid Biosciences Inc. | -93.43 Million USD | 45.521% |
| BriaCell Therapeutics Corp. | -4.77 Million USD | -966.73% |
| Immuneering Corporation | -58.06 Million USD | 12.331% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | 1587300.842% |
| Silo Pharma, Inc. | -3.62 Million USD | -1303.71% |
| Belite Bio, Inc | -31.52 Million USD | -61.444% |
| XOMA Corporation | -39.36 Million USD | -29.316% |
| ARS Pharmaceuticals, Inc. | -67.44 Million USD | 24.531% |
| Bionomics Limited | -9.83 Million USD | -417.45% |
| Apogee Therapeutics, Inc. | -83.98 Million USD | 39.392% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | -47.089% |
| uniQure N.V. | -253.1 Million USD | 79.889% |
| Cassava Sciences, Inc. | -95.68 Million USD | 46.804% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -596.318% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | 60.695% |
| Forte Biosciences, Inc. | -32.47 Million USD | -56.731% |
| Anebulo Pharmaceuticals, Inc. | -8.05 Million USD | -532.28% |
| Enlivex Therapeutics Ltd. | -28.21 Million USD | -80.38% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | -15610.349% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | -356.885% |
| FibroBiologics, Inc. Common Stock | -15.9 Million USD | -220.115% |
| Altimmune, Inc. | -87.93 Million USD | 42.115% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | 44.72% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | -47.089% |
| Compugen Ltd. | -12.51 Million USD | -306.692% |
| Peak Bio, Inc. | -1356.23 USD | -3753063.623% |
| Zevra Therapeutics, Inc. | -48.59 Million USD | -4.74% |
| Benitec Biopharma Inc. | -22.49 Million USD | -126.33% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | 78.993% |
| NKGen Biotech, Inc. Common Stock | -28.54 Million USD | -78.333% |
| Zura Bio Limited | -60.56 Million USD | 15.953% |
| PolyPid Ltd. | -20.26 Million USD | -151.204% |
| Aileron Therapeutics, Inc. | -15.61 Million USD | -226.02% |
| NKGen Biotech, Inc. Warrants | -28.54 Million USD | -78.333% |
| Instil Bio, Inc. | -146.12 Million USD | 65.165% |
| argenx SE | -216.02 Million USD | 76.437% |
| Immunome, Inc. | -28.27 Million USD | -80.049% |
| Compass Therapeutics, Inc. | -48.47 Million USD | -5.01% |
| Verona Pharma plc | -52.46 Million USD | 2.985% |
| enGene Holdings Inc. Warrants | -94.77 Million USD | 46.291% |
| Shattuck Labs, Inc. | -87.61 Million USD | 41.903% |
| CervoMed Inc. | -2.17 Million USD | -2243.669% |
| LENZ Therapeutics, Inc. | -122.24 Million USD | 58.361% |
| Plus Therapeutics, Inc. | -12.69 Million USD | -301.02% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | -5.662% |
| Moolec Science SA | -52.07 Million USD | 2.254% |
| Enveric Biosciences, Inc. | -17.13 Million USD | -196.975% |
| Inovio Pharmaceuticals, Inc. | -130.39 Million USD | 60.962% |
| AnaptysBio, Inc. | -143.16 Million USD | 64.445% |
| Design Therapeutics, Inc. | -66.32 Million USD | 23.254% |
| Leap Therapeutics, Inc. | -80.98 Million USD | 37.149% |
| NeurAxis, Inc. | -6.66 Million USD | -663.772% |
| Seelos Therapeutics, Inc. | -37.75 Million USD | -34.838% |
| Lumos Pharma, Inc. | -36.57 Million USD | -39.189% |
| Achilles Therapeutics plc | -70.44 Million USD | 27.74% |
| enGene Holdings Inc. Common Stock | -94.77 Million USD | 46.291% |
| 180 Life Sciences Corp. | -22.13 Million USD | -129.97% |
| Opiant Pharmaceuticals, Inc. | 5.82 Million USD | 973.209% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | -1984.92% |
| Nutriband Inc. | -5.12 Million USD | -893.826% |
| ORIC Pharmaceuticals, Inc. | -109.74 Million USD | 53.62% |
| CG Oncology, Inc. Common stock | -55.43 Million USD | 8.173% |
| Fractyl Health, Inc. Common Stock | -50.55 Million USD | -0.695% |
| Rani Therapeutics Holdings, Inc. | -65.27 Million USD | 22.022% |
| MoonLake Immunotherapeutics | -54.1 Million USD | 5.929% |
| Palisade Bio, Inc. | -12.28 Million USD | -314.474% |
| Tourmaline Bio, Inc. | -45.37 Million USD | -12.177% |
| Beam Therapeutics Inc. | -156.47 Million USD | 67.469% |
| Neurogene Inc. | -52.28 Million USD | 2.648% |
| Mirum Pharmaceuticals, Inc. | -136.49 Million USD | 62.707% |
| AEON Biopharma, Inc. | -48.36 Million USD | -5.253% |
| CARGO Therapeutics, Inc. Common Stock | -93.01 Million USD | 45.278% |
| Sesen Bio, Inc. | -50.84 Million USD | -0.121% |
| Enliven Therapeutics, Inc. | -81.93 Million USD | 37.873% |
| Kiora Pharmaceuticals, Inc. | -12.35 Million USD | -312.157% |
| Iovance Biotherapeutics, Inc. | -427.43 Million USD | 88.091% |
| Taysha Gene Therapies, Inc. | -105.19 Million USD | 51.613% |
| Athira Pharma, Inc. | -116.7 Million USD | 56.384% |
| Vaccinex, Inc. | -19.74 Million USD | -157.755% |
| HCW Biologics Inc. | -23.57 Million USD | -115.904% |
| XOMA Corporation | -39.36 Million USD | -29.316% |
| Nektar Therapeutics | -243.1 Million USD | 79.062% |
| Arvinas, Inc. | -394.8 Million USD | 87.107% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | 27073.987% |
| Merus N.V. | -149.2 Million USD | 65.885% |
| Omega Therapeutics, Inc. | -93.49 Million USD | 45.554% |
| Quince Therapeutics, Inc. | -31.26 Million USD | -62.833% |
| Rezolute, Inc. | -68.42 Million USD | 25.608% |
| Clene Inc. | -43.24 Million USD | -17.716% |
| Indaptus Therapeutics, Inc. | -15.42 Million USD | -230.054% |
| BeyondSpring Inc. | -21.54 Million USD | -136.312% |
| Synlogic, Inc. | -55.16 Million USD | 7.722% |
| Allarity Therapeutics, Inc. | -12.08 Million USD | -321.266% |
| Phio Pharmaceuticals Corp. | -10.64 Million USD | -378.308% |
| Peak Bio, Inc. | -1356.23 USD | -3753063.623% |
| Werewolf Therapeutics, Inc. | -32.46 Million USD | -56.789% |
| Krystal Biotech, Inc. | 17.9 Million USD | 384.303% |
| Karyopharm Therapeutics Inc. | -118.42 Million USD | 57.017% |
| SpringWorks Therapeutics, Inc. | -341.34 Million USD | 85.088% |
| Lipella Pharmaceuticals Inc. | -4.6 Million USD | -1005.01% |
| MannKind Corporation | 15.12 Million USD | 436.45% |
| Ikena Oncology, Inc. | -74.39 Million USD | 31.581% |
| Cyclerion Therapeutics, Inc. | -12.59 Million USD | -304.205% |
| Gyre Therapeutics, Inc. | 20.32 Million USD | 350.413% |
| Gossamer Bio, Inc. | -172.15 Million USD | 70.432% |
| CohBar, Inc. | -12.06 Million USD | -321.868% |
| Cognition Therapeutics, Inc. | -25.5 Million USD | -99.543% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | -69.53% |
| Legend Biotech Corporation | -477.87 Million USD | 89.348% |
| Mural Oncology plc | -192.72 Million USD | 73.588% |
| Biora Therapeutics, Inc. | -114.05 Million USD | 55.371% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | -215.272% |
| Disc Medicine, Inc. | -91.02 Million USD | 44.08% |
| Champions Oncology, Inc. | -5.05 Million USD | -907.153% |
| REGENXBIO Inc. | -239.46 Million USD | 78.744% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | -374.908% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 8.707% |
| Cellectar Biosciences, Inc. | -38.76 Million USD | -31.297% |
| Edgewise Therapeutics, Inc. | -112.8 Million USD | 54.877% |
| Vaxart, Inc. | -74.72 Million USD | 31.88% |
| PharmaCyte Biotech, Inc. | - USD | Infinity% |
| Aldeyra Therapeutics, Inc. | -35.2 Million USD | -44.573% |
| Cellectis S.A. | -98.09 Million USD | 48.11% |
| Longeveron Inc. | -20.06 Million USD | -153.746% |
| Repare Therapeutics Inc. | -114.27 Million USD | 55.456% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 88.41% |
| Inozyme Pharma, Inc. | -74.81 Million USD | 31.961% |
| Revolution Medicines, Inc. | -430.58 Million USD | 88.178% |
| Nymox Pharmaceutical Corporation | -6.28 Million USD | -709.374% |
| Third Harmonic Bio, Inc. | -30.78 Million USD | -65.324% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | 31.758% |
| AN2 Therapeutics, Inc. | 4.9 Million USD | 1138.171% |
| Anixa Biosciences, Inc. | -10.96 Million USD | -364.218% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 101.105% |
| Denali Therapeutics Inc. | -179.97 Million USD | 71.717% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | -53363.502% |
| Veru Inc. | -89.97 Million USD | 43.427% |
| Corvus Pharmaceuticals, Inc. | -26.87 Million USD | -89.38% |
| Cingulate Inc. | -22.95 Million USD | -121.774% |
| Passage Bio, Inc. | -98.34 Million USD | 48.24% |
| Context Therapeutics Inc. | -25.06 Million USD | -103.114% |
| Exicure, Inc. | -15.53 Million USD | -227.573% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | 75.298% |
| Oramed Pharmaceuticals Inc. | -36.97 Million USD | -37.661% |
| Scinai Immunotherapeutics Ltd. | -5.96 Million USD | -753.681% |
| Rhythm Pharmaceuticals, Inc. | -168.46 Million USD | 69.785% |
| Nuvalent, Inc. | -149.49 Million USD | 65.95% |
| ABVC BioPharma, Inc. | -8.13 Million USD | -525.909% |
| Carisma Therapeutics, Inc. | -85.89 Million USD | 40.739% |
| Unicycive Therapeutics, Inc. | -30.17 Million USD | -68.671% |
| OmniAb, Inc. | -49.73 Million USD | -2.354% |
| Anew Medical, Inc. | -1.3 Million USD | -3812.974% |
| Fennec Pharmaceuticals Inc. | -12.36 Million USD | -311.691% |
| Lipocine Inc. | -16.32 Million USD | -211.846% |
| Lexeo Therapeutics, Inc. Common Stock | -66.67 Million USD | 23.652% |
| Nautilus Biotechnology, Inc. | -74.3 Million USD | 31.495% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | -33.483% |
| G1 Therapeutics, Inc. | -39.01 Million USD | -30.47% |
| Bellerophon Therapeutics, Inc. | -22.18 Million USD | -129.462% |
| Sage Therapeutics, Inc. | -545.07 Million USD | 90.661% |
| Ocugen, Inc. | -64.82 Million USD | 21.481% |
| Mind Medicine (MindMed) Inc. | -92.57 Million USD | 45.013% |
| Q32 Bio Inc. | -86.5 Million USD | 41.156% |
| Brainstorm Cell Therapeutics Inc. | -16.92 Million USD | -200.712% |
| Alumis Inc. Common Stock | -156.89 Million USD | 67.556% |
| Equillium, Inc. | -12.13 Million USD | -319.357% |
| Kyverna Therapeutics, Inc. | -58.47 Million USD | 12.947% |
| Coya Therapeutics, Inc. | -7.9 Million USD | -544.05% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | -169.878% |
| Galera Therapeutics, Inc. | -46.69 Million USD | -9.016% |
| Evelo Biosciences, Inc. | -106.34 Million USD | 52.135% |
| Comera Life Sciences Holdings, Inc. | -17.88 Million USD | -184.579% |
| Dominari Holdings Inc. | -22.44 Million USD | -126.834% |
| Edesa Biotech, Inc. | -8.19 Million USD | -521.498% |
| vTv Therapeutics Inc. | -25.41 Million USD | -100.305% |
| Bio-Techne Corporation | 326.66 Million USD | 115.582% |
| Agios Pharmaceuticals, Inc. | -384.86 Million USD | 86.774% |
| Harmony Biosciences Holdings, Inc. | 216.38 Million USD | 123.523% |
| Prelude Therapeutics Incorporated | -131.1 Million USD | 61.176% |
| Candel Therapeutics, Inc. | -37.43 Million USD | -35.988% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | 66.313% |
| Nkarta, Inc. | -120.48 Million USD | 57.751% |
| BioCardia, Inc. | -11.56 Million USD | -340.325% |
| Iterum Therapeutics plc | -34.58 Million USD | -47.199% |